Chemotherapy-induced hair loss

What it is

Chemotherapy-induced hair loss is hair thinning or loss caused by chemotherapy, affecting about 65% of patients. Doctors also call it chemotherapy-induced alopecia (CIA). It happens because many chemotherapy drugs damage rapidly dividing cells, including the cells in hair follicles. Hair loss may involve the scalp, eyebrows, eyelashes, beard, underarm hair, and pubic hair, not just the hair on the head.

CIA is one of the most visible and distressing side effects of cancer treatment. The risk depends mainly on the specific drug, the dose, the schedule, and whether several drugs are combined. Some drug groups are more likely to cause alopecia than others. In published reviews, alopecia has been reported in more than 80% of patients receiving anti-microtubule agents, 60% to 100% with topoisomerase inhibitors, more than 60% with alkylating agents, and 10% to 50% with antimetabolites.

Hair loss from chemotherapy is usually temporary, but not always. Most people start to notice shedding about 2 to 4 weeks after treatment begins. Regrowth often starts after chemotherapy ends, commonly within 3 to 6 months, although the new hair may initially look or feel different. A smaller number of patients develop persistent or permanent thinning, especially after certain regimens such as taxane-based treatment.

Feature	Typical pattern
When it starts	About 2 to 4 weeks after chemotherapy begins
Where it occurs	Scalp most often, but can affect body hair too
Severity	Mild thinning to near-complete hair loss
Regrowth	Often begins after treatment, commonly within 3 to 6 months
Permanent change	Uncommon, but can happen in some patients

How it works

Hair follicles normally cycle through growth, transition, and resting phases. Chemotherapy targets fast-growing cells, which is useful against cancer but also affects normal tissues with high cell turnover. Hair matrix keratinocytes in actively growing follicles are especially vulnerable. When these cells are injured, the hair shaft becomes weak and breaks or sheds.

This process is often called anagen effluvium. Because scalp hair follicles spend a large proportion of time in the active growth phase, scalp hair is commonly affected first and most noticeably. The same mechanism can affect eyelashes, eyebrows, and body hair.

Not every chemotherapy drug causes the same degree of alopecia. Risk is higher with agents such as anthracyclines and taxanes, and lower with some other regimens. Targeted therapies and endocrine therapies can also cause hair thinning, but their pattern is often different from classic CIA.

Evidence and uses

CIA is not a disease that needs a separate cure, but it is an important treatment side effect that can affect body image, privacy, work, social life, and mental health. For many patients, preparing for hair loss before chemotherapy starts is as important as managing nausea or fatigue.

The best-supported preventive option is scalp cooling, also called scalp hypothermia. This uses a cooled cap before, during, and after chemotherapy infusion to reduce blood flow and drug delivery to the scalp. Reviews show that scalp cooling can reduce the chance or severity of hair loss in selected patients, but it does not work for everyone and is not suitable for every cancer type or treatment plan. Success depends on the chemotherapy regimen, cap fit, cooling protocol, and hair characteristics.

Common management approaches include:

1. Scalp cooling: Best studied preventive method for many solid-tumour regimens.
2. Cosmetic support: Wigs, scarves, caps, eyebrow pencils, false eyelashes, and head coverings.
3. Gentle hair care: Mild shampoo, less heat styling, avoiding harsh chemical treatments.
4. Minoxidil after chemotherapy: May help speed regrowth in some patients, but it does not reliably prevent CIA during treatment.

Minoxidil is sometimes used after chemotherapy to support regrowth, but evidence is stronger for shortening the time to visible regrowth than for preventing hair loss in the first place. It should only be used after discussion with the treating team, because scalp irritation and shedding can occur, and not every patient needs it.

In India, access to scalp-cooling systems varies by cancer centre and cost. Many patients rely on practical coping measures such as early haircutting, wig fitting before shedding starts, and support from oncology nurses or psycho-oncology services. If a centre offers scalp cooling, patients should ask whether it is appropriate for their regimen and whether there are added charges.

When to see a clinician

Tell your oncology team before treatment starts if hair loss is a major concern for you. They can often estimate your risk based on the exact chemotherapy plan and discuss whether scalp cooling is an option.

You should also speak to a clinician if:

• hair loss is patchy, inflamed, painful, or associated with rash
• the scalp develops sores, infection, severe itching, or crusting
• hair does not begin to regrow months after treatment ends
• thinning continues long after chemotherapy is over
• you are considering minoxidil, supplements, or herbal products

Persistent hair loss deserves medical review because not all post-treatment alopecia is due only to chemotherapy. Iron deficiency, thyroid disease, endocrine therapy, stress, nutritional problems, radiation, and other medicines can contribute. A dermatologist may help if the pattern is unusual or prolonged.

Limitations and open questions

Although CIA is common, predicting exactly who will lose hair and how much remains imperfect. Published incidence figures vary because studies use different chemotherapy regimens, definitions, and grading systems. The emotional impact also varies widely between patients.

Scalp cooling has the best evidence for prevention, but it is not fully effective and may be less practical in some settings. Questions remain about which regimens respond best, how to optimise cap fit for different hair types, and how to improve access in routine care. Evidence in humans is still limited for many proposed preventive products, supplements, oils, and herbal remedies.

Permanent chemotherapy-induced alopecia is now better recognised than it was in the past, but its true frequency is still uncertain and likely depends on treatment type. More long-term studies are needed to identify who is at highest risk and which treatments help recovery.

Patients should be cautious about over-the-counter products marketed for "chemo hair regrowth." Many have little or no direct evidence in CIA, and some may irritate the scalp or interact with treatment if taken by mouth. It is safest to check with the oncology team or a pharmacist before using any medicine, supplement, or herbal preparation during cancer treatment.